Pharming Group N.V. ADR PHAR

$9.75 -0.20 (-2.01%)

Valuation

Market cap
690,085,000
Revenue TTM
$376,130,000
Net income TTM
$2,850,000
PE ratio
82.92
Forward PE
46.28
Profit margin
0.76%
Debt to equity
0.02

Trading

Volume
12,400
Avg volume
27,456
Day's range
$9.75 – $9.96
Shares out
70,778,000
Stochastic %K
0%
Beta
-0.05
Analysts
Strong Sell
Price target
$38.00

Price

Company profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniol...

Show more

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops Joenja, an oral small molecule PI3K? inhibitor. It has a development collaboration and license agreement with Novartis. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Industry
Biotechnology
Sector
Healthcare
Phone
31 71 524 7400
Website
https://www.pharming.com
Address
Darwinweg 24, Leiden, Netherlands

Latest news

Stocktwits

Ruconestor Oct 2, 3:14 PM
$PHAR
0 replies
De_Monitor Sep 30, 9:28 PM
$PHAR Pharming closed below $10!! Since IPO Stockprice down 50%!
0 replies
De_Monitor Sep 30, 4:58 PM
$PHVS $PHAR My prediction: Pharvaris gets acquired. With approval expected within the next few months and a potentially very valuable oral HAE franchise approaching commercialization, I think the window for a takeover is opening fast. A larger pharma could prefer to acquire Pharvaris before approval or shortly after, rather than wait until the full commercial value of the franchise becomes visible. Wouldn’t surprise me at all if Pharvaris gets bought out around approval. 💰🚀
0 replies
De_Monitor Sep 30, 4:55 PM
$PHAR @PharmingIR Pharming nearing the 52 week low again!
0 replies
De_Monitor Sep 29, 10:06 PM
$PHAR Pharming IPO: $20. Today: $10. @PharmingIR, without the CEO there’s apparently nothing left but the same old narrative. No answers to critical questions, just more PR. Stop pushing narratives and start giving investors actual answers.
0 replies
PharmingIR Sep 29, 12:53 PM
$PHAR Today we announced that the Board of Directors and Fabrice Chouraqui have mutually agreed that Mr. Chouraqui will step down as Chief Executive Officer and Executive Director, with immediate effect. To ensure continuity of leadership, the Board of Directors has appointed Mrs. Leverne Marsh, Chief Commercial Officer, and Mr. Kenneth Lynard, Chief Financial Officer, as Interim Co-CEOs, effective immediately. Mrs. Marsh will lead the patient-focused operations while Mr. Lynard will lead the global corporate functions. Please note that this announcement does not affect our outlook, pipeline, or commercial portfolio. Read the full announcement here: https://www.pharming.com/our-news
1 replies
Ruconestor Sep 29, 10:34 AM
$PHAR Good news, Pharming wants the best and stragety and Mr courage wasn't good enough. Good decision
2 replies
BarKnar Sep 29, 8:59 AM
$PHAR Choraqui sacked.
0 replies